Condition

Gastrointestinal Neuroendocrine Tumor

ClinicalTrials.gov condition label

Clinical trials3

Recruiting1

Common interventions2

Lead sponsors shown3

Clinical trials

3 shown

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)NCT05196087 · 2022-07-20

RECRUITING

Multicenter Trial of ESK981 in Patients With Select Solid TumorsNCT05988918 · 2024-04-19

ACTIVE_NOT_RECRUITING

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsNCT05997056 · 2023-10-20

COMPLETED

Common interventions

ESK981DRUG1nab-sirolimusDRUG1

Leading sponsors

Aadi Bioscience, Inc.1University Health Network, Toronto1University of Michigan Rogel Cancer Center1

Trial status mix

ACTIVE_NOT_RECRUITING1

COMPLETED1

RECRUITING1

Phase mix

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.